Sammanfattning
Early detection of prostate cancer (PC) using prostate-specific antigen (PSA) in blood reduces PC-death among unscreened men. However, due to modest specificity of PSA at commonly used cut-offs, there are urgent needs for additional biomarkers contributing enhanced risk classification among men with modestly elevated PSA.
Originalspråk | engelska |
---|---|
Sidor (från-till) | 951-962 |
Tidskrift | Proteomics Clinical Applications |
Volym | 8 |
Nummer | 11-12 |
DOI | |
Status | Published - 2014 |
Ämnesklassifikation (UKÄ)
- Cell- och molekylärbiologi